Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All Candida albicans ( n = 251), Candida tropicalis ( n = 51), Candida krusei ( n = 16), and Candida dubliniensis ( n = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five C. glabrata isolates ( n = 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on fks1 and fks2 . Candida parapsilosis ( n = 92) and Candida orthopsilosis ( n = 10) displayed higher CD101 MIC values (ranges, 0.5 to 4 μg/ml and 0.12 to 2 μg/ml, respectively), and similar results were observed for the other echinocandins tested. Fluconazole resistance was noted among 11.0% of Candida glabrata isolates, 4.3% of C. parapsilosis isolates, and 2.0% of C. albicans and C. tropicalis isolates. The activity of CD101 against Aspergillus fumigatus ( n = 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. These isolates had wild-type susceptibility to itraconazole, voriconazole, and posaconazole. The echinocandins had limited activity against Cryptococcus neoformans ( n = 19). CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. The long half-life profile is very desirable for the prevention and treatment of serious fungal infections, especially in patients who can then be discharged from the hospital to complete antifungal therapy on an outpatient basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299 · cited 1×
“Despite the broad utilization of echinocandins to treat invasive candidiasis in critically ill hospitalized patients, clinical resistance to these agents remains uncommon, although both breakthrough infections and acquired resistance mutations have been noted in some species of Candida (1).”
BackgroundPfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
Self-citationNational Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · cited 2×
“Although a recent report highlighted the lack of reproducibility of caspofungin MIC results when isolates were tested using CLSI reference broth microdilution methods (13), the results were included in this study.”
BackgroundSelf-citationCastanheira, M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.02.009 · Cited by 159
Self-citationPfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.04.008 · Cited by 127
Self-citationCD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility
Krishnan, B. R., James, K. D., Polowy, K., Bryant, B. J., Vaidya, A., Smith, S., & Laudeman, C. P. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.89 · Cited by 98 · cited 1×
“) is a novel echinocandin antifungal agent that displays chemical stability in plasma, in aqueous solution, and at elevated temperatures and that also possesses a long-acting pharmacokinetic profile (4, 5).”
BackgroundCastanheira, M., Woosley, L. N., Messer, S. A., Diekema, D. J., Jones, R. N., & Pfaller, M. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01674-13 · Cited by 82
Self-citationCD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Cited by
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz390 · Cited by 82
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68
Self-citationWe can do better: a fresh look at echinocandin dosing
Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx448 · Cited by 46
Chandra, J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-17 · Cited by 36
Metadata
- Authors
- Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-03
- Volume
- 61
- Issue
- 3
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2570990198
- Cited by
- 53
- References
- 10
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. https://app.cochat.ai/papers/10.1128/aac.02045-16
- The paper
- Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017). Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02045-16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.